Abstract
A 58-year-old man with melanoma treated with ipilimumab/nivolumab presented with pain, limited joint mobility, and proximal weakness without oculobulbar weakness, dyspnea, or rash. EMG demonstrated positive sharp waves, fibrillations, and myopathic units. Extremity MRI showed diffuse fascial and mild muscle enhancement consistent with fasciitis/mild myositis (Figure). Creatinine kinase was normal. PET-CT demonstrated diffusely fluorodeoxyglucose-avid lymph nodes and muscles; lymph node biopsy revealed granulomatous inflammation suggesting immune checkpoint inhibitor-related inflammatory reaction. Biceps biopsy demonstrated perifascicular atrophy (PA) and fascial/perimysial perivascular inflammation (Figure).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
